CORRESP Filing
BridgeBio Oncology Therapeutics, Inc.
Date: Sept. 8, 2025 · CIK: 0001869105 · Accession: 0001193125-25-198323
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-289940
Letter
Re: BridgeBio Oncology Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-289940 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), BridgeBio Oncology Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-289940) (the “Registration Statement”), so that it may become effective at 4:01 pm Eastern time on September 10, 2025, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Maggie Wong, Esq. of Goodwin Procter LLP at (415) 733-6071.
BridgeBio Oncology Therapeutics, Inc. 256 E. Grand Avenue, Suite 104 South San Francisco, CA 94080 September 8, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549
Very truly yours, BridgeBio
Oncology Therapeutics, Inc.
By:
Show Raw Text
CORRESP 1 filename1.htm CORRESP BridgeBio Oncology Therapeutics, Inc. 256 E. Grand Avenue, Suite 104 South San Francisco, CA 94080 September 8, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: BridgeBio Oncology Therapeutics, Inc. Registration Statement on Form S-1 File No. 333-289940 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), BridgeBio Oncology Therapeutics, Inc. (the “Company”) hereby requests acceleration of the effective date of its Registration Statement on Form S-1 (File No. 333-289940) (the “Registration Statement”), so that it may become effective at 4:01 pm Eastern time on September 10, 2025, or as soon thereafter as practicable, unless we or our outside counsel, Goodwin Procter LLP, request by telephone that such Registration Statement be declared effective at some other time. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. If you have any questions regarding this request, please contact Maggie Wong, Esq. of Goodwin Procter LLP at (415) 733-6071. Very truly yours, BridgeBio Oncology Therapeutics, Inc. By: /s/ Eli Wallace Name: Eli Wallace Title: Chief Executive Officer cc: Maggie Wong, Goodwin Procter LLP